387 related articles for article (PubMed ID: 26415231)
1. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma cancer stem cells.
Gao M; Kong Y; Yang G; Gao L; Shi J
Oncotarget; 2016 Jun; 7(23):35466-77. PubMed ID: 27007154
[TBL] [Abstract][Full Text] [Related]
3. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X
Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
5. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
6. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.
Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X
Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cells in multiple myeloma.
Ghosh N; Matsui W
Cancer Lett; 2009 May; 277(1):1-7. PubMed ID: 18809245
[TBL] [Abstract][Full Text] [Related]
8. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
[No Abstract] [Full Text] [Related]
9. The myeloma stem cell concept, revisited: from phenomenology to operational terms.
Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K
Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712
[TBL] [Abstract][Full Text] [Related]
10. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
11. Concise review: Defining and targeting myeloma stem cell-like cells.
Abe M; Harada T; Matsumoto T
Stem Cells; 2014 May; 32(5):1067-73. PubMed ID: 24449391
[TBL] [Abstract][Full Text] [Related]
12. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
Gooding S; Edwards CM
Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
[TBL] [Abstract][Full Text] [Related]
13. Targeting Multiple Myeloma Cancer Stem Cells with Natural Products - Lessons from Other Hematological Malignancies.
Issa ME; Cretton S; Cuendet M
Planta Med; 2017 Jun; 83(9):752-760. PubMed ID: 28472843
[TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
16. Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells.
Joseph D; Gonsky JP; Blain SW
PLoS One; 2018; 13(11):e0206368. PubMed ID: 30383785
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.
Blatt K; Herrmann H; Stefanzl G; Sperr WR; Valent P
Oncotarget; 2016 Oct; 7(40):65627-65642. PubMed ID: 27582537
[TBL] [Abstract][Full Text] [Related]
18. Fact or fiction--identifying the elusive multiple myeloma stem cell.
Kellner J; Liu B; Kang Y; Li Z
J Hematol Oncol; 2013 Dec; 6():91. PubMed ID: 24314019
[TBL] [Abstract][Full Text] [Related]
19. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
[TBL] [Abstract][Full Text] [Related]
20. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
